Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 54

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Alpha-1 antitrypsin deficiency+1

Not recruiting

Study Comparing INBRX-101 and Human Alpha1-Proteinase Inhibitor for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human ALPHA-1-PROTEINASE inhibitor immunoglobulin G fusion protein, recombinant
  • Sponsor:Sanofi AATD Inc.

Diabetic nephropathy+2

Not recruiting

Remote Study on Empagliflozin and Finerenone for Reducing Kidney Issues in Type 2 Diabetes Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Gaucher's disease type III+1

Not recruiting

Study of Eliglustat alone or with imiglucerase in children and adolescents aged 2-17 years with Gaucher disease type 1 and type 3

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Eliglustat Tartrate
  • Sponsor:Genzyme Corp.

Gaucher's disease type I

Not recruiting

Study on the Long-term Safety of FLT201 for Patients with Gaucher Disease Type 1

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant
  • Sponsor:Spur Therapeutics Limited

Metachromatic leukodystrophy

Not recruiting

Study on the Effects of Atidarsagene Autotemcel for Patients with Late Juvenile Metachromatic Leukodystrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Latent autoimmune diabetes in adults

Not recruiting

Study on Latent Autoimmune Diabetes in Adults (LADA) Patients: Evaluating Diabetes Status 3 Years After Treatment with Glutamate Decarboxylase 2

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glutamate decarboxylase 2, human, recombinant
  • Sponsor:Norwegian University Of Science And Technolology

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

Hyperinsulinaemic hypoglycaemia+1

Not recruiting

Study on the Effects of Pasireotide in Patients with Low Blood Sugar After Bariatric Surgery

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Recordati AG

Niemann-Pick disease

Not recruiting

Study on the Safety and Long-Term Effects of Efavirenz for Adults and Late-Onset Juvenile Niemann-Pick Type C Disease with Cognitive Impairment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Aprepitant
  • Sponsor:Bellvitge University Hospital

Iron deficiency anaemia+1

Not recruiting

Study on Daily vs. Alternate Day Iron Supplements for Treating Iron Deficiency Anemia in Pregnant Women

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years
  • Substances:Iron
  • Sponsor:University College Dublin

Glycogen storage disease type I

Not recruiting

Study of Pariglasgene Brecaparvovec and Prednisolone for Adults with Glycogen Storage Disease Type Ia

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Metachromatic leukodystrophy

Not recruiting

Study of Atidarsagene Autotemcel for Treating Early Onset Metachromatic Leukodystrophy (MLD) in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.